Mandate

Vinge advises Wilson Therapeutics in connection with the offer from Alexion

April 11, 2018

Alexion has announced a public cash offer to the shareholders of Wilson Therapeutics AB.


The offer values Wilson Therapeutics at approximately SEK 6,564 million. 
 
Vinge advises Wilson Therapeutics in connection with the offer. Vinge’s team is primarily composed of Erik Sjöman, Christian Lindhé, Astrid Karlsson and Philip Åberg. 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025